20151 WEBCAST: State-of-the-Art Solutions for Myelofibrosis: The Intersection of JAK Inhibitors, Allogeneic Transplant, and Other Strategies for Patient Care
In this activity, a panel of experts in the management of myelofibrosis (MF) offers learners an update on the modern diagnostic and risk assessment strategies that have informed a more considered treatment approach to symptomatic disease. An emerging paradigm, in which potentially curative hematopoietic cell transplantation (HCT) is used in conjunction with Janus kinase (JAK) inhibitor therapy, is discussed, along with an expert-led assessment of JAK inhibitor options in development for MF and how these additions to the treatment arsenal will be used alongside standard approaches. For professionals who are looking to pair recent evidence on JAK inhibitors with HCT and other options in the management of MF, this educational event is an essential disease management resource.
This activity can be accessed using the following URL: www.peerview.com/UQB
This activity has been designed to meet the educational needs of hematologist-oncologists, oncologists, BMT specialists, BMT nurse specialists, and other clinicians involved in the management of myelofibrosis.
Upon completion of this activity, participants should be better able to:
- Identify clinical symptoms and molecular/mutational features that can be used to diagnose and risk-stratify myelofibrosis
- Discuss the current treatment role of JAK inhibitors and allogeneic transplantation in the management of myelofibrosis
- Cite recent efficacy and safety evidence on established and emerging JAK inhibitors and other targeted agents in the management of myelofibrosis
- Develop risk-adapted treatment plans for patients with symptomatic myelofibrosis, including those who did not respond to previous JAK inhibitor therapy or are eligible for allogeneic transplantation
This activity is supported by an educational grant from Celgene Corporation.
In accordance with ACCME requirements, The Medical College of Wisconsin has a conflict of interest policy that requires faculty to disclose relevant financial relationships related to the content of their presentations/materials. Any potential conflicts are resolved so that presentations are evidence-based and scientifically balanced.
Co-Chair and Presenter
Prithviraj Bose, MD
Associate Professor, Department of Leukemia, Division of Cancer Medicine
The University of Texas MD Anderson Cancer Center
Prithviraj Bose, MD, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for Celgene Corporation; CTI BioPharma Corp.; Incyte Corporation; and Kartos Therapeutics, Inc.
Grant/Research Support from Astellas Pharma US, Inc.; Blueprint Medicines Corporation; Celgene Corporation; CTI BioPharma Corp.; Incyte Corporation; Kartos Therapeutics, Inc.; NS Pharma,Inc.; Pfizer, Inc.; and Promedior, Inc.
Speakers Bureau participant with CTI BioPharma Corp. and Kartos Therapeutics, Inc.
Co-Chair and Presenter
Jeanne M. Palmer, MD
Associate Professor, Division of Hematology and Oncology
Vice Chair and Section Lead, Division of Hematology
Program Director, Blood and Marrow Transplant Program
Jeanne M. Palmer, MD, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for CTI BioPharma Corp.
PVI, PeerView Institute for Medical Education
Carmine DeLuca has no financial interests/relationships or affiliations in relation to this activity.
The Medical College of Wisconsin (MCW) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by MCW for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations. Providership, Credit, and Support This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of The Medical College of Wisconsin and PVI, PeerView Institute for Medical Education. The Medical College of Wisconsin is accredited by the ACCME to provide continuing medical education for physicians.
Disclosure of Unlabeled Use The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use. No endorsement of unapproved products or uses is made or implied by coverage of these products or uses in our reports. No responsibility is taken for errors or omissions in reports. For approved prescribing information, please consult the manufacturer’s product labeling. The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PeerView or any of its partners, providers, and/or supporters.
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of The Medical College of Wisconsin and PVI, PeerView Institute for Medical Education. The Medical College of Wisconsin is accredited by the ACCME to provide continuing medical education for physicians.
The Medical College of Wisconsin designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Hours of Participation for Allied Health Care Professionals:
The Medical College of Wisconsin designates this activity for up to 1.0 hours of participation for continuing education for allied health professionals.
This CME activity is jointly provided by The Medical College of Wisconsin and PVI, PeerView Institute for Medical Education.
- 1.00 AMA PRA Category 1 Credit(s)™AMA PRA Category 1 Credit(s)™
- 1.00 Hours of ParticipationHours of Participation credit.